ArticleJournal of industrial microbiology & biotechnology2019
Natural product drug discovery in the genomic era: realities, conjectures, misconceptions, and opportunities.
Article in Journal of industrial microbiology & biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed.
- When context matters: community and environmental context to elicit natural products.Essays in biochemistry · 2026Review
- De-novo assembly of 82 bacterial genomes using Nanopore sequencing and prediction of biosynthetic capacity.Scientific data · 2026Article
- Genome Mining-Driven Isolation of New Gromomycins and Insights into Their Mode of Action.ACS chemical biology · 2026Article
- Comparative volatilomics identifies ubiquitous sulfur compounds inhibiting the fungal pathogenMicrobiology spectrum · 2026Article
- The antiSMASH database version 5.Nucleic acids research · 2026Article
- Hidden in the Pangenome? Machine Learning-Driven Discovery of Antimicrobial Potential inBioinformatics and biology insights · 2026Article
- Research Progress on the Regulation and Developmental Utilization of Bioactive Metabolites Synthesis inJournal of fungi (Basel, Switzerland) · 2025Review
- Genome mining reveals the distribution of biosynthetic gene clusters in Alternaria and related fungal taxa within the family Pleosporaceae.BMC genomics · 2025Article
- Multi-omics approaches: transforming the landscape of natural product isolation.Functional & integrative genomics · 2025Review
- Microbial secondary metabolites: advancements to accelerate discovery towards application.Nature reviews. Microbiology · 2025Review
- Identification of a critical gene involved in the biosynthesis of the polyene macrolide lavencidin inApplied and environmental microbiology · 2025Article
- Whole-Genome Profiling of Endophytic Strain B.L.Ns.14 fromMicroorganisms · 2024Article
- Heterocyclic phytometabolites formononetin and arbutin preventToxicology reports · 2024Article
- Reclassification of two Nocardiopsis species using whole genome analysis.Antonie van Leeuwenhoek · 2024Article
- Progress in the Study of Natural Antimicrobial Active Substances inMolecules (Basel, Switzerland) · 2024Review
- The role of Streptomyces to achieve the United Nations sustainable development goals. Burning questions in searching for new compounds.Microbial biotechnology · 2024Article
- Actinomycetes are a natural resource for sustainable pest control and safeguarding agriculture.Archives of microbiology · 2024Review
- Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy.Medical oncology (Northwood, London, England) · 2024Review
- The Complete Genomic Sequence of Microbial Transglutaminase Producer, Streptomyces mobaraensis DSM40587.Biochemical genetics · 2024Article
- Mining Biosynthetic Gene Clusters ofMicroorganisms · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural product discovery from microorganisms provided important sources for antibiotics, anti-cancer agents, immune-modulators, anthelminthic agents, and insecticides during a span of 50 years starting in the 1940s, then became less productive because of rediscovery issues, low throughput, and lack of relevant new technologies to unveil less abundant or not easily detected drug-like natural products. In the early 2000s, it was observed from genome sequencing that Streptomyces species encode about ten times as many secondary metabolites as predicted from known secondary metabolomes. This gave rise to a new discovery approach-microbial genome mining. As the cost of genome sequencing dropped, the numbers of sequenced bacteria, fungi and archaea expanded dramatically, and bioinformatic methods were developed to rapidly scan whole genomes for the numbers, types, and novelty of secondary metabolite biosynthetic gene clusters. This methodology enabled the identification of microbial taxa gifted for the biosynthesis of drug-like secondary metabolites. As genome sequencing technology progressed, the realities relevant to drug discovery have emerged, the conjectures and misconceptions have been clarified, and opportunities to reinvigorate microbial drug discovery have crystallized. This perspective addresses these critical issues for drug discovery.
Indexed as
Identifiers
30484124What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.